Charting Only, page-104

I wasn't replying to you, i was more replying to the other comments but accidentally deleted the reply tag. [Replying to speccys more recent post...it keeps on deleting the reply tag]

I think when I say that, I do not assume the success of each drug. If you put where both drugs are at:
- Both haven't started Phase 1
- Both are in the IND stage (Century got theirs approved last week and CHM will be expecting it early next year or late this year).
- Both are speculative

I think they are quite comparable in terms of their stage in the development process and if I was to pick one. I would choose the one with the more advanced tech.

Also, I've not invested in either Nkarta or Century Therapeutics. I'm waiting for prices to go down lower, biotechs do not do well in high-interest rate environments. But I merely brought them up to say that there might be better programs out there other than CHM

The main basis of my divestment in the company is their CLTX CAR-T. I see too many red flags for it to produce results that will change market sentiment. Maybe I'm wrong and these series of posts could make me look like a dud but there are too many unknowns to ride when you either could:
- Buy at even lower prices on a negative result of CLTX CAR-T
- Buy 50% higher than the price on a positive result of CLTX CAR-T with more clarity on how the product works.

Again just a risk management play.